DK1937671T3 - Benzimidazolthiophenforbindelser som PLK-inhibitorer - Google Patents
Benzimidazolthiophenforbindelser som PLK-inhibitorerInfo
- Publication number
- DK1937671T3 DK1937671T3 DK06813896.5T DK06813896T DK1937671T3 DK 1937671 T3 DK1937671 T3 DK 1937671T3 DK 06813896 T DK06813896 T DK 06813896T DK 1937671 T3 DK1937671 T3 DK 1937671T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzimidazolthiophene
- compounds
- plk inhibitors
- plk
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71433705P | 2005-09-06 | 2005-09-06 | |
| US78624406P | 2006-03-27 | 2006-03-27 | |
| PCT/US2006/033683 WO2007030361A2 (en) | 2005-09-06 | 2006-08-28 | Benzimidazole thiophene compounds as plk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1937671T3 true DK1937671T3 (da) | 2010-04-26 |
Family
ID=37631488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06813896.5T DK1937671T3 (da) | 2005-09-06 | 2006-08-28 | Benzimidazolthiophenforbindelser som PLK-inhibitorer |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7595330B2 (da) |
| EP (1) | EP1937671B1 (da) |
| JP (1) | JP5002597B2 (da) |
| KR (1) | KR20080047585A (da) |
| AR (1) | AR055616A1 (da) |
| AT (1) | ATE452132T1 (da) |
| AU (1) | AU2006287766B2 (da) |
| BR (1) | BRPI0615668A2 (da) |
| CA (1) | CA2621879A1 (da) |
| CR (1) | CR9786A (da) |
| CY (1) | CY1109916T1 (da) |
| DE (1) | DE602006011192D1 (da) |
| DK (1) | DK1937671T3 (da) |
| EA (1) | EA014111B1 (da) |
| ES (1) | ES2337929T3 (da) |
| HR (1) | HRP20100122T1 (da) |
| IL (1) | IL189897A0 (da) |
| JO (1) | JO2578B1 (da) |
| MA (1) | MA29816B1 (da) |
| MX (1) | MX2008003173A (da) |
| NO (1) | NO20081160L (da) |
| NZ (1) | NZ566345A (da) |
| PE (1) | PE20070518A1 (da) |
| PL (1) | PL1937671T3 (da) |
| PT (1) | PT1937671E (da) |
| SI (1) | SI1937671T1 (da) |
| TW (1) | TW200800967A (da) |
| WO (1) | WO2007030361A2 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009538305A (ja) * | 2006-05-23 | 2009-11-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド |
| US20090326029A1 (en) * | 2006-06-02 | 2009-12-31 | Kevin Wayne Kuntz | Non-cyclic substituted benzimidazole thiophene benzyl ether compounds |
| PE20080710A1 (es) * | 2006-06-02 | 2008-08-07 | Smithkline Beecham Corp | Compuestos de tiofeno de bencimidazol |
| US7615643B2 (en) | 2006-06-02 | 2009-11-10 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| EP2123627B1 (en) * | 2007-01-19 | 2013-11-20 | Ube Industries, Ltd. | Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group |
| JP2010531887A (ja) * | 2007-06-26 | 2010-09-30 | グラクソスミスクライン エルエルシー | ベンズイミダゾールチオフェンの調製方法 |
| WO2009003911A1 (en) * | 2007-06-29 | 2009-01-08 | 4Sc Ag | Thiophene-imidazopyridines |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| WO2009151914A1 (en) * | 2008-05-27 | 2009-12-17 | Smithkline Beecham Corporation | Methods for treating neoplasms with a combination of a plk inhibitor and retinoid |
| WO2009154645A1 (en) * | 2008-06-20 | 2009-12-23 | Smithkline Beecham Corporation | Methods for the treatment of central nervous system tumors |
| JP2012512223A (ja) | 2008-12-18 | 2012-05-31 | エフ．ホフマン−ラ ロシュ アーゲー | チアゾリル−ベンズイミダゾール類 |
| WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
| LT2496567T (lt) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Nauji benzopirano kinazės moduliatoriai |
| PT2705029T (pt) | 2011-05-04 | 2019-02-01 | Rhizen Pharmaceuticals S A | Novos compostos como moduladores de proteína quinases |
| PT2870157T (pt) | 2012-07-04 | 2017-11-27 | Rhizen Pharmaceuticals S A | Inibidores seletivos de delta pi3k |
| US20230158158A1 (en) | 2020-03-27 | 2023-05-25 | Uppthera | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
| KR102574152B1 (ko) * | 2020-03-27 | 2023-09-05 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| CA2341409A1 (en) | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
| MXPA05001544A (es) * | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
| AU2003903440A0 (en) * | 2003-07-04 | 2003-07-17 | James Hardie International Finance B.V. | Rainscreen apparatus and method |
| EP1685128A1 (en) * | 2003-10-16 | 2006-08-02 | Smithkline Beecham Corporation | Process for preparing benzimidazole thiophenes |
| JP4721428B2 (ja) | 2003-10-20 | 2011-07-13 | 日本精工株式会社 | ステアリング装置 |
| GB0402809D0 (en) | 2004-02-09 | 2004-03-10 | Glaxo Group Ltd | Chemical compounds |
| EP1924572B1 (en) * | 2005-09-06 | 2009-12-30 | SmithKline Beecham Corporation | Regioselective process for preparing benzimidazole thiophenes |
| JP2009507020A (ja) * | 2005-09-06 | 2009-02-19 | スミスクライン ビーチャム コーポレーション | Ｐｌｋ調節物質としてのルベンゾイミダゾールチオフェン化合物 |
| EP2474546A1 (en) | 2006-01-23 | 2012-07-11 | Vertex Pharmaceuticals Inc. | Thiophene-carboxamides useful as inhibitors of protein kinases |
| PE20080710A1 (es) * | 2006-06-02 | 2008-08-07 | Smithkline Beecham Corp | Compuestos de tiofeno de bencimidazol |
| US20090326029A1 (en) * | 2006-06-02 | 2009-12-31 | Kevin Wayne Kuntz | Non-cyclic substituted benzimidazole thiophene benzyl ether compounds |
-
2006
- 2006-08-28 MX MX2008003173A patent/MX2008003173A/es active IP Right Grant
- 2006-08-28 US US11/467,577 patent/US7595330B2/en not_active Expired - Fee Related
- 2006-08-28 DK DK06813896.5T patent/DK1937671T3/da active
- 2006-08-28 PL PL06813896T patent/PL1937671T3/pl unknown
- 2006-08-28 NZ NZ566345A patent/NZ566345A/en not_active IP Right Cessation
- 2006-08-28 JO JO2006286A patent/JO2578B1/en active
- 2006-08-28 SI SI200630582T patent/SI1937671T1/sl unknown
- 2006-08-28 ES ES06813896T patent/ES2337929T3/es active Active
- 2006-08-28 KR KR1020087007794A patent/KR20080047585A/ko not_active Ceased
- 2006-08-28 TW TW095131590A patent/TW200800967A/zh unknown
- 2006-08-28 WO PCT/US2006/033683 patent/WO2007030361A2/en not_active Ceased
- 2006-08-28 BR BRPI0615668-1A patent/BRPI0615668A2/pt not_active IP Right Cessation
- 2006-08-28 US US12/065,668 patent/US7786127B2/en not_active Expired - Fee Related
- 2006-08-28 HR HR20100122T patent/HRP20100122T1/hr unknown
- 2006-08-28 JP JP2008529190A patent/JP5002597B2/ja not_active Expired - Fee Related
- 2006-08-28 EP EP06813896A patent/EP1937671B1/en not_active Not-in-force
- 2006-08-28 AR ARP060103742A patent/AR055616A1/es not_active Application Discontinuation
- 2006-08-28 CA CA002621879A patent/CA2621879A1/en not_active Abandoned
- 2006-08-28 AT AT06813896T patent/ATE452132T1/de active
- 2006-08-28 PE PE2006001041A patent/PE20070518A1/es not_active Application Discontinuation
- 2006-08-28 DE DE602006011192T patent/DE602006011192D1/de active Active
- 2006-08-28 EA EA200800546A patent/EA014111B1/ru not_active IP Right Cessation
- 2006-08-28 PT PT06813896T patent/PT1937671E/pt unknown
- 2006-08-28 AU AU2006287766A patent/AU2006287766B2/en not_active Ceased
-
2008
- 2008-02-29 CR CR9786A patent/CR9786A/es not_active Application Discontinuation
- 2008-03-03 IL IL189897A patent/IL189897A0/en unknown
- 2008-03-05 NO NO20081160A patent/NO20081160L/no not_active Application Discontinuation
- 2008-03-31 MA MA30794A patent/MA29816B1/fr unknown
-
2010
- 2010-03-09 CY CY20101100224T patent/CY1109916T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1019I2 (fr) | Inhibiteurs de kinase de type biaryl-meta-pyrimidine | |
| LTPA2020501I1 (lt) | Pakeistieji enaminokarbonilo junginiai | |
| ATE452132T1 (de) | Benzimidazolthiophenverbindungen als plk- inhibitoren | |
| DK2086939T3 (da) | Pyridiacarboxamid som II-beta-HSDI-inhibitorer | |
| DK1789041T3 (da) | Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer | |
| NO20082514L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
| DK1959951T3 (da) | Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer | |
| LTC1907382I2 (lt) | Nitrokatechnolio dariniai, kaip COMT inhibitoriai | |
| DK2125748T3 (da) | Acylaminopyrazol som FGFR inhibitorer | |
| DK1797042T3 (da) | Indozolonderivater som 11B-HSD1-inhibitorer | |
| DK1926722T3 (da) | Substituerede benzimidazoler som kinaseinhibitorer | |
| DK2139892T3 (da) | Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer | |
| ATE490254T1 (de) | Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer | |
| DK2094263T3 (da) | 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer | |
| CY2013047I1 (el) | Ενωσεις διαρυλυδαντοϊνης | |
| DK2094708T3 (da) | En pyrrolopyrazin som syk-kinase-inhibitor | |
| DK2102205T3 (da) | Pyridopyrazinderivater anvendelige som herbicidale forbindelser | |
| DK1586319T3 (da) | Thiadiazolidinoner som GSK-3-inhibitorer | |
| DK1960352T3 (da) | 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer | |
| DK2021335T3 (da) | Heterocykliske forbindelser som C-FMS-kinasehæmmere | |
| ATE524477T1 (de) | Aziridinylepothilonverbindungen | |
| DK2220070T3 (da) | 2-benzylpyridazinonderivater som Met-kinaseinhibitorer | |
| DK2383271T3 (da) | Aminoquinoloner som GSK-3-inhibitorer | |
| DK2078001T3 (da) | Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer | |
| DK1846394T3 (da) | Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer |